A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The report recommends the pursuit of legislation that would enable price negotiation in Medicare Parts B and D, with those negotiated prices also available to the federal marketplace, commercial plans and employers who want to participate; Medicare Part D reform, including a cap on beneficiary out-of-pocket spending; and legislation that would slow price increases over time on existing drugs and speed entry of biosimilars and generics to the marketplace while increasing their prescribing by clinicians.   
  
The report also suggests a series of executive tools to be undertaken by HHS, including the testing of several models that would use value-based payments in Medicare Part B or provide additional cost-sharing support for Medicare Part D Low-income Subsidy Beneficiaries for using biosimilars or generics, as well as efforts to curb the use of anti-competitive tactics like pay-for-delay and evergreening. A separate test of cost-of-care models would look at whether such efforts can produce changes in drug utilization, reduce total spending and improve patient outcomes. 
  
The report restates the Administration’s continued support of the 340B Drug Pricing Program. 
 

Related News Articles

Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…
Headline
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement…
News
Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis…
News
The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via…
Headline
The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug…